- Novartis announced last week that European regulators have approved its follow-on biologic epoetin alfa, which is biosimilar to J&J’s Eprex. Pharmalot posted this story today about J&J’s reaction.
- The WSJ Health Blog had this interesting post last week reporting that more clinical trials are now under way in China than in India.
- Adams Respiratory Therapeutics is facing a patent challenge by Perrigo over its Mucinex cough medicine. Bloomberg recently published this report; MarketWatch.com had this one.
- The Wall St. Journal published this interesting article (subscription) a couple weeks ago about a drug development partnership between Eli Lilly and Chi-Med, a Chinese biotechnology company.
- FDA Law Blog had this post last month about impending FDA enforcement action on marketed unapproved drugs.
- Finally, a couple oldies but goodies from Pharma’s Cutting Edge: Ariad v. Lilly patent litigation; response to Richard Epstein’s Overdose.
Recent Posts
- Hikma v. Vanda: Oral Argument Recap
- Teva v. Lilly should not be read as creating a new 112 rule for method of use claims
- Should ANDA filers be using the PTAB to mount early challenges to OB patents?
- Switching to WordPress
- Judge Hughes concurrence highlights post grant review appeal standing issue for pharma cases
Orange Book Blog 
Leave a comment